TROG 03.06/VCOG PR 01-03 - TOAD - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A collaborative randomised phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Prof Paul Keall, Image X Director and VITaL trial chief investigator

15 May, 2025

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

LATEST NEWS: 15 May 2025 A novel imaging modality

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A collaborative randomised phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA.

TROG 03.07 – Non Small Cell Lung Cancer

TROG 03.02

Related Post

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

Trial data-sharing made easier with HeSANDA initiative

TROG 03.06/VCOG PR 01-03 – TOAD

A collaborative randomised phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA.

TROG 03.07 – Non Small Cell Lung Cancer

TROG 03.02

Related Post

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

Trial data-sharing made easier with HeSANDA initiative